Abstract:3599 Background: Tislelizumab (TIS), an anti-programmed cell death protein 1 (PD-1) antibody, demonstrated improved anti-tumor response and tolerable safety in patients (pts) with previously treated, locally advanced unresectable or metastatic microsatellite instability high/deficient mismatch repair (MSI-H/dMMR) solid tumors, including colorectal cancer (CRC; NCT03736889). Recent studies of other anti-PD-1 antibodies indicate potential clinical benefit of neoadjuvant anti-PD-1 therapy in pts with resectable MSI-H/dMMR CRC. Here, we report efficacy and safety outcomes of neoadjuvant TIS from a multicenter phase II trial (NCT05116085) in this population. Methods: Pts aged ≥18 years with stage II/III MSI-H/dMMR CRC, ECOG PS 0-1, evaluable disease per RECIST v1.1, and eligible for R0 (complete) resection were enrolled. Pts received TIS 200 mg IV every 3 weeks for 3 cycles followed by surgical resection within 10 weeks of first TIS dose. The primary endpoint was major pathological response (MPR) rate (proportion of pts with ≤10% residual viable tumor in the surgically resected primary tumor). Secondary endpoints included pathological complete response (pCR) rate (proportion of pts with absence of residual tumor in the surgically resected specimen), and safety. The R0 resection rate was an exploratory endpoint. Results: Overall, 33 pts were enrolled across eight sites in China. The median age of enrolled pts was 52.0 years (range: 23-84), 14 (42.4%) pts were male. Ten (30.3%) pts had rectal cancer and 23 (69.7%) colon cancer. At study entry, clinical tumor (T) stage was reported as T2, T3, and T4 in 1 (3.0%), 7 (21.2%), and 25 (75.8%) pts, respectively, and node (N) stage as N0, N1, and N2 in 6 (18.2%), 14 (42.4%), and 13 (39.4%) pts, respectively. All pts had a metastasis (M) stage of M0. A total of 29 (87.9%) pts underwent surgery and were evaluable for efficacy endpoints. Surgery was not performed in 4 pts, 3 of whom were managed non-operatively (1 pt had progressive disease). MPR and pCR rates were 89.7% and 62.1%, respectively (Table). Any-grade and grade ≥3 TIS-related adverse events (TRAEs) were reported in 20 (60.6%) and 1 (3.0%) pts, respectively. Two (6.1%) pts experienced serious TRAEs; no TRAEs led to death or surgery cancellation. One pt (3.0%) experienced a TRAE (grade 2 hypothyroidism) leading to surgery delay. No grade ≥3 or serious TIS-related surgery-relevant adverse events were reported. Immune-mediated adverse events were reported in 10 (30.3%) pts (all grade 1-2). Conclusions: Neoadjuvant TIS was associated with high MPR and pCR rates and an acceptable safety profile, and did not compromise surgery in pts with resectable MSI-H/dMMR CRC. Clinical trial information: NCT05116085 . [Table: see text]

Trans-catheter arterial infusion chemotherapy(TAI) significantly reduces tumor size of colorectal neoplasm in pTNM stage IIIB

137P Tislelizumab Combined with Chemotherapy As Neoadjuvant Therapy for Stage IIIA-IIIB(N2) Potentially Resectable Squamous Non-Small-cell Lung Cancer (TACT)

Evaluation of the T-restaging and Effect after Neoadjuvant Chemotherapy in Advanced Gastric Carcinoma Using Double Contrast-Enhanced Ultrasonography

Preoperative (neoadjuvant) Therapy with Tislelizumab for Locally Advanced Colorectal Cancer with High Microsatellite Instability or Deficient Mismatch Repair: an Open-Label, Single-Arm, Multicenter Phase II Study.

THE EFFECT OF NADROPARIN AND INTRAPORTAL INFUSION OF TEGAFUR ON PREVENT LIVER METASTASIS AFTER COLORECTAL CANCER SURGERY

Diagnostic Value of MR T2WI and Contrast Enhanced CT in the Pre-Operative T Staging of Primary Rectal Carcinoma

Application value of different sequences magnetic resonance imaging in rectal cancer re-staging after neoadjuvant chemoradiation therapy

Preoperative T staging of advanced colorectal cancer by computed tomography colonography

Effect of preoperative adjuvant transcatheter hepatic arterial chemoembolization on prognosis of resectable huge hepatocellular carcinoma

Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial.

Prognostic Impact of Tumor-Infiltrating Immune Cells on Efficacy of Neoadjuvant Chemotherapy in Patients with Advanced or Metastatic Ovarian Cancer: A Retrospective Study

Relativity Between the Expression of Transforming Growth Factor Betal and the Apoptosis and Proliferation of Rectal Cancer Cell after Preoperative Transarterial Chemotherapy

A novel stratification scheme combined with internal arteries in CT imaging for guiding postoperative adjuvant transarterial chemoembolization in hepatocellular carcinoma: a retrospective cohort study

Postoperative adjuvant TACE for patients of hepatocellular carcinoma in AJCC stage I: friend or foe? a propensity score analysis

Clinical research combining preoperative magnetic resonance imaging staging with laparoscopic surgery on the therapy of rectal carcinoma

Intelligent diagnosis value of preoperative T staging of colorectal cancer based on MR medical imaging

The effect of postoperative adjuvant transcatheter hepatic arterial chemoembolization on survival of patients after resection of huge hepatocellular carcinoma

[Effect of Preoperative Radiotherapy As an Adjunctive Approach on Proliferation and Apoptosis of Cancer Cells in Rectal Cancer].

Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: A reappraisal

Prognostic factors for transarterial chemoembolization combined with sustained oxaliplatin-based hepatic arterial infusion chemotherapy of colorectal cancer liver metastasis.

Effects of tumor-infiltrating lymphocytes on nonresponse rate of neoadjuvant chemotherapy in patients with invasive breast cancer